MedKoo product information:

 Granisetron hydrochloride

granisetron hydrochloride is the hydrochloride salt of an indazole derivative with antiemetic properties. As a selective serotonin receptor antagonist, granisetron competitively blocks the action of serotonin at 5-hydroxytryptamine3 (5-HT3) receptors, resulting in the suppression of chemotherapy- and radiotherapy-induced nausea and vomiting. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

According to http://en.wikipedia.org/wiki/Granisetron, Granisetron was developed by chemists working at the British drug company Beecham around 1988 and is available as a generic. It is produced by Roche Laboratories under the trade name Kytril. The drug was approved in the United Kingdom in 1991 and in United States in 1994 by the FDA. A granisetron transdermal patch with the trade name Sancuso was approved by the US FDA on September 12, 2008. Sancuso is manufactured by ProStrakan, Inc., a pharmaceutical company headquartered in Bedminster, NJ, with global headquarters in Scotland. Granisetron breaks down slowly, staying in the body for a long time. One dose usually lasts 4 to 9 hours and is usually administered once or twice daily. This drug is removed from the body by the liver and kidneys.

DRUG DESCRIPTION

KYTRIL Tablets and KYTRIL Oral Solution contain granisetron hydrochloride, an antinauseant and antiemetic agent. Chemically it is endo-N-(9-methyl-9-azabicyclo [3.3.1] non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride with a molecular weight of 348.9 (312.4 free base). Its empirical formula is C18H24N4O•HCl. Granisetron hydrochloride is a white to off-white solid that is readily soluble in water and normal saline at 20°C.

Tablets for Oral Administration: Each white, triangular, biconvex, film-coated KYTRIL Tablet contains 1.12 mg granisetron hydrochloride equivalent to granisetron, 1 mg. Inactive ingredients are: hydroxypropyl methylcellulose, lactose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, sodium starch glycolate, and titanium dioxide.

Oral Solution: Each 10 mL of clear, orange-colored, orange-flavored KYTRIL Oral Solution contains 2.24 mg of granisetron hydrochloride equivalent to 2 mg granisetron. Inactive ingredients: citric acid anhydrous, FD&C Yellow No. 6, orange flavor, purified water, sodium benzoate, and sorbitol.

CLINICAL PHARMACOLOGY

Granisetron is a selective 5-hydroxytryptamine3 (5-HT3) receptor antagonist with little or no affinity for other serotonin receptors, including 5-HT1; 5-HT1A; 5-HT1B/C; 5-HT2; for alpha1-, alpha2-, or beta-adrenoreceptors; for dopamine-D2; or for histamine-H1; benzodiazepine; picrotoxin or opioid receptors. Serotonin receptors of the 5-HT3 type are located peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area postrema. During chemotherapy that induces vomiting, mucosal enterochromaffin cells release serotonin, which stimulates 5-HT3 receptors. This evokes vagal afferent discharge, inducing vomiting. Animal studies demonstrate that, in binding to 5-HT3 receptors, granisetron blocks serotonin stimulation and subsequent vomiting after emetogenic stimuli such as cisplatin. In the ferret animal model, a single granisetron injection prevented vomiting due to high-dose cisplatin or arrested vomiting within 5 to 30 seconds. In most human studies, granisetron has had little effect on blood pressure, heart rate or ECG. No evidence of an effect on plasma prolactin or aldosterone concentrations has been found in other studies.

Following single and multiple oral doses, KYTRIL Tablets slowed colonic transit in normal volunteers. However, KYTRIL had no effect on oro-cecal transit time in normal volunteers when given as a single intravenous (IV) infusion of 50 mcg/kg or 200 mcg/kg.

 1: Aapro MS, Walko CM. Aprepitant: drug-drug interactions in perspective. Ann Oncol. 2010 May 20. [Epub ahead of print] PubMed PMID: 20488873.

2: Zang J, Hou M, Gou HF, Qiu M, Wang J, Zhou XJ, Luo DY, Yang Y, Jiang M, Cao D, Bi F, Xu F, Shen Y, Yi C. Antiemetic activity of megestrol acetate in patients receiving chemotherapy. Support Care Cancer. 2010 Apr 26. [Epub ahead of print] PubMed PMID: 20419494.

3: Billio A, Morello E, Clarke MJ. Serotonin receptor antagonists for highly emetogenic chemotherapy in adults. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD006272. Review. PubMed PMID: 20091591.

4: Tian W, Wang Z, Zhou J, Zhang S, Wang J, Chen Q, Huang C, Pan L, Zhang L, Huang J, Shen H, Lin T. Randomized, double-blind, crossover study of palonosetron compared with granisetron for the prevention of chemotherapy-induced nausea and vomiting in a Chinese population. Med Oncol. 2010 Jan 5. [Epub ahead of print] PubMed PMID: 20049561.

5: Ho CL, Su WC, Hsieh RK, Lin ZZ, Chao TY. A randomized, double-blind, parallel, comparative study to evaluate the efficacy and safety of ramosetron plus dexamethasone injection for the prevention of acute chemotherapy-induced nausea and vomiting. Jpn J Clin Oncol. 2010 Apr;40(4):294-301. Epub 2009 Dec 20. PubMed PMID: 20026457.

6: Schulmeister L. Granisetron transdermal system: a new option to help prevent chemotherapy-induced nausea and vomiting. Clin J Oncol Nurs. 2009 Dec;13(6):711-4. PubMed PMID: 19948469.

7: Duggan ST, Curran MP. Transdermal granisetron. Drugs. 2009;69(18):2597-605. doi: 10.2165/11202780-000000000-00000. Review. PubMed PMID: 19943709.

8: Bello CL, Mulay M, Huang X, Patyna S, Dinolfo M, Levine S, Van Vugt A, Toh M, Baum C, Rosen L. Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of sunitinib. Clin Cancer Res. 2009 Nov 15;15(22):7045-52. Epub 2009 Nov 10. PubMed PMID: 19903787.

9: Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet. 2009;48(12):761-804. doi: 10.2165/11318070-000000000-00000. PubMed PMID: 19902987.

10: Matsumoto Y, Shimizu K, Kinoshita H, Shimizu C, Uchitomi Y. Suicide associated with corticosteroid use during chemotherapy: case report. Jpn J Clin Oncol. 2010 Feb;40(2):174-6. Epub 2009 Oct 19. PubMed PMID: 19841103.

11: Tsukuda M, Ishitoya J, Mikami Y, Matsuda H, Katori H, Horiuchi C, Kimura M, Taguchi T, Yoshida T, Nagao J, Sakuma Y, Toth G. Antiemetic effects of granisetron and dexamethasone combination therapy during cisplatin-containing chemotherapy for head and neck cancer: dexamethasone dosage verification trial. Int J Clin Oncol. 2009 Aug;14(4):337-43. Epub 2009 Aug 25. PubMed PMID: 19705245.

12: Yokokawa T, Matsusaka S, Shouji D, Imada H, Nakamoto E, Kamisugi K, Suzuki W, Shirai T, Takahashi G, Kawakami K, Shinozaki E, Suenaga M, Mizunuma N, Hatake K, Hama T. [Efficacy of preventive treatment for delayed emesis induced by FOLFOX4 chemotherapy]. Yakugaku Zasshi. 2009 Aug;129(8):949-55. Japanese. PubMed PMID: 19652501.

13: Jain V, Mitra JK, Rath GP, Prabhakar H, Bithal PK, Dash HH. A randomized, double-blinded comparison of ondansetron, granisetron, and placebo for prevention of postoperative nausea and vomiting after supratentorial craniotomy. J Neurosurg Anesthesiol. 2009 Jul;21(3):226-30. PubMed PMID: 19543000.

14: Taguchi K, Iihara H, Ishihara M, Komori Y, Tanizawa K, Matsuura K, Itoh Y. Comparison of antiemetic efficacy between single and repeated treatments with a 5-HT3 receptor antagonist in breast cancer patients with high-risk emetogenic chemotherapy. Anticancer Res. 2009 May;29(5):1721-5. PubMed PMID: 19443393.

15: Yonemura M, Katsumata N, Hashimoto H, Satake S, Kaneko M, Kobayashi Y, Takashima A, Kato Y, Takeuchi M, Fujiwara Y, Yamamoto H, Hojo T. Randomized controlled study comparing two doses of intravenous granisetron (1 and 3 mg) for acute chemotherapy-induced nausea and vomiting in cancer patients: a non-inferiority trial. Jpn J Clin Oncol. 2009 Jul;39(7):443-8. Epub 2009 Apr 24. PubMed PMID: 19395466.

16: Howell J, Smeets J, Drenth HJ, Gill D. Pharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy-induced nausea and vomiting. J Oncol Pharm Pract. 2009 Dec;15(4):223-31. Epub . PubMed PMID: 19304880.

17: Lajolo PP, de Camargo B, del Giglio A. Omission of day 2 of antiemetic medications is a cost saving strategy for improving chemotherapy-induced nausea and vomiting control: results of a randomized phase III trial. Am J Clin Oncol. 2009 Feb;32(1):23-6. PubMed PMID: 19194119.

18: Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol. 2009 Feb;10(2):115-24. Epub 2009 Jan 8. Erratum in: Lancet Oncol. 2010 Mar;11(3)226. PubMed PMID: 19135415.

19: Jordan K, Kinitz I, Voigt W, Behlendorf T, Wolf HH, Schmoll HJ. Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy. Eur J Cancer. 2009 May;45(7):1184-7. Epub 2009 Jan 8. PubMed PMID: 19135359.

20: Morrow T. Transdermal patch tailors antinausea treatment. Manag Care. 2008 Dec;17(12):47-8. PubMed PMID: 19127767.

21: Ozdemir E, Akgedik K, Akdogan S, Kansu E. The lollipop with strawberry aroma may be promising in reduction of infusion-related nausea and vomiting during the infusion of cryopreserved peripheral blood stem cells. Biol Blood Marrow Transplant. 2008 Dec;14(12):1425-8. PubMed PMID: 19041066.

22: Zhang Q, Huang XE, Gao LL. A clinical study on the premedication of paclitaxel liposome in the treatment of solid tumors. Biomed Pharmacother. 2009 Sep;63(8):603-7. Epub 2008 Oct 31. PubMed PMID: 19019625.

23: Kruse GB, Amonkar MM, Smith G, Skonieczny DC, Stavrakas S. Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population. J Manag Care Pharm. 2008 Nov-Dec;14(9):844-57. PubMed PMID: 19006441.

24: Yu Z, Liu W, Wang L, Liang H, Huang Y, Si X, Zhang H, Liu D, Zhang H. The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial. Support Care Cancer. 2009 Jan;17(1):99-102. Epub 2008 Sep 30. PubMed PMID: 18825421.

25: Tuca A, Roca R, Sala C, Porta J, Serrano G, González-Barboteo J, Gómez-Batiste X. Efficacy of granisetron in the antiemetic control of nonsurgical intestinal obstruction in advanced cancer: a phase II clinical trial. J Pain Symptom Manage. 2009 Feb;37(2):259-70. Epub 2008 Sep 11. PubMed PMID: 18789638.

26: Reddy GK, Gralla RJ, Hesketh PJ. Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis. Support Cancer Ther. 2006 Apr 1;3(3):140-2. PubMed PMID: 18632487.

27: Liu ZF, Guo QS, Zhang XQ, Yang XG, Guan F, Fu Z, Wang MY. Biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer. Am J Clin Oncol. 2008 Jun;31(3):259-63. PubMed PMID: 18525305.

28: Bursztejn AC, Tréchot P, Cuny JF, Schmutz JL, Barbaud A. Cutaneous adverse drug reactions during chemotherapy: consider non-antineoplastic drugs. Contact Dermatitis. 2008 Jun;58(6):365-8. PubMed PMID: 18503688.

29: Okuyama K, Yoshimoto K, Iwase O, Ozeki T, Yamada Y. [Clinical evaluation of antiemetic effects of 5-hydroxytryptamine receptor type 3 (5HT3 receptor) antagonists based on changes in eating condition in cancer patients receiving chemotherapy]. Yakugaku Zasshi. 2008 Apr;128(4):649-55. Japanese. PubMed PMID: 18379183.

30: Nakade S, Ohno T, Kitagawa J, Hashimoto Y, Katayama M, Awata H, Kodama Y, Miyata Y. Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting. Cancer Chemother Pharmacol. 2008 Dec;63(1):75-83. Epub 2008 Mar 4. PubMed PMID: 18317761.

31: Yavas O, Yazici M, Eren O, Boruban C, Artac M, Genc M. The acute effect of tropisetron on ECG parameters in cancer patients. Support Care Cancer. 2008 Sep;16(9):1011-5. Epub 2008 Feb 1. PubMed PMID: 18239945.

32: Buchanan D, Muirhead K. Intractable nausea and vomiting successfully related with granisetron 5-hydroxytryptamine type 3 receptor antagonists in Palliative Medicine. Palliat Med. 2007 Dec;21(8):725-6. PubMed PMID: 18073263.

33: Bhatnagar S, Gupta D, Mishra S, Srikanti M, Singh M, Arora R. Preemptive antiemesis in patients undergoing modified radical mastectomy: oral granisetron versus oral ondansetron in a double-blind, randomized, controlled study. J Clin Anesth. 2007 Nov;19(7):512-6. PubMed PMID: 18063205.

34: Hamberg P, De Jong FA, Brandsma D, Verweij J, Sleijfer S. Irinotecan-induced central nervous system toxicity. Report on two cases and review of the literature. Acta Oncol. 2008;47(5):974-8. Review. PubMed PMID: 17924208.

35: Gurpide A, Sadaba B, Martin-Algarra S, Azanza JR, Lopez-Picazo JM, Campanero MA, Cabello JP, Gil-Aldea I, de la Cruz S, Fernandez Gallego V, Reyna C, Olier Garate C, Blanco-Prieto MJ, Ceballos J, Garcia-Foncillas J, Perez-Gracia JL. Randomized crossover pharmacokinetic evaluation of subcutaneous versus intravenous granisetron in cancer patients treated with platinum-based chemotherapy. Oncologist. 2007 Sep;12(9):1151-5. PubMed PMID: 17914085.

36: Nogaki T, Funahashi H, Sonohara F, Sueoka S, Konishi S, Ohshima K, Ito H, Sako T, Harada A. [A case of anaphylactic shock caused by granisetron]. Gan To Kagaku Ryoho. 2007 Sep;34(9):1517-9. Japanese. PubMed PMID: 17876160.

37: Hamadani M, Chaudhary L, Awan FT, Khan JK, Kojouri K, Ozer H, Tfayli A. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist? J Oncol Pharm Pract. 2007 Jun;13(2):69-75. PubMed PMID: 17873106.

38: Wilkes G. Antiemetic agents. Oncology (Williston Park). 2007 Jul;21(8 Suppl):48. PubMed PMID: 17844897.

39: Woo JS. Nasal absorption studies of granisetron in rats using a validated high-performance liquid chromatographic method with mass spectrometric detection. Arch Pharm Res. 2007 Jun;30(6):778-84. PubMed PMID: 17679558.

40: Abali H, Celik I. Tropisetron, ondansetron, and granisetron for control of chemotherapy-induced emesis in Turkish cancer patients: a comparison of efficacy, side-effect profile, and cost. Cancer Invest. 2007 Apr-May;25(3):135-9. PubMed PMID: 17530482.

41: Berrak SG, Ozdemir N, Bakirci N, Turkkan E, Canpolat C, Beker B, Yoruk A. A double-blind, crossover, randomized dose-comparison trial of granisetron for the prevention of acute and delayed nausea and emesis in children receiving moderately emetogenic carboplatin-based chemotherapy. Support Care Cancer. 2007 Oct;15(10):1163-8. Epub 2007 Mar 20. PubMed PMID: 17372773.

42: Takenaka M, Okamoto Y, Ikeda K, Hashimoto R, Ueda T, Kurokawa N, Takagi T, Uejima E. [Comparison of antiemetic efficacy of 5-HT3 receptor antagonists in orthopedics cancer patients receiving high-dose chemotherapy]. Gan To Kagaku Ryoho. 2007 Mar;34(3):403-7. Japanese. PubMed PMID: 17353632.

43: Abenhardt W, Bosse D, Böning L, Bojko P, Hitz H, Völkl S, Fromm M, Mittermüller J, Göldel N, Schick HD, Dietzfelbinger H, Hinke A. [Treatment of chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists]. Dtsch Med Wochenschr. 2006 Dec 1;131(48):2707-12. German. PubMed PMID: 17123235.

44: Tomono H, Ito Y, Watanabe T. [Successful antiemetic treatment of TSUMURA Rikkunshi-to Extract Granules for ethical use in addition to other antiemetic agents in neoadjuvant chemotherapy for an advanced breast cancer patient]. Gan To Kagaku Ryoho. 2006 Aug;33(8):1129-31. Japanese. PubMed PMID: 16912533.

45: Luisi FA, Petrilli AS, Tanaka C, Caran EM. Contribution to the treatment of nausea and emesis induced by chemotherapy in children and adolescents with osteosarcoma. Sao Paulo Med J. 2006 Mar 2;124(2):61-5. PubMed PMID: 16878187.

46: Shikimori M, Komatsu H, Hashimoto K, Yamashita Y. Granisetron reduces clinical and histological response to intra-arterial neoadjuvant chemotherapy in oral squamous cell carcinoma. Int J Oral Maxillofac Surg. 2006 Sep;35(9):800-2. Epub 2006 Jul 18. PubMed PMID: 16854561.

47: Inoue S, Endo K, Endo K, Nakamura R, Itou H. [Relationship between neurotransmitter blood noradrenalin and nausea/emesis after chemotherapy for lung cancer]. Gan To Kagaku Ryoho. 2006 Jul;33(7):931-6. Japanese. PubMed PMID: 16835482.

48: Yamakuni H, Nakayama H, Matsui S, Imazumi K, Matsuo M, Mutoh S. Inhibitory effect of zacopride on Cisplatin-induced delayed emesis in ferrets. J Pharmacol Sci. 2006 May;101(1):99-102. Epub 2006 Apr 29. PubMed PMID: 16651699.

49: Miyata M, Yasuda K, Burioka N, Takane H, Suyama H, Shigeoka Y, Endo M, Kurai J, Morita M, Igishi T, Shimizu E. The influence of granisetron on the pharmacokinetics and pharmacodynamics of docetaxel in Asian lung cancer patients. Cancer J. 2006 Jan-Feb;12(1):69-72. PubMed PMID: 16613665.

50: Pickering G, Loriot MA, Libert F, Eschalier A, Beaune P, Dubray C. Analgesic effect of acetaminophen in humans: first evidence of a central serotonergic mechanism. Clin Pharmacol Ther. 2006 Apr;79(4):371-8. PubMed PMID: 16580905.

51: Babaoglu MO, Bayar B, Aynacioglu AS, Kerb R, Abali H, Celik I, Bozkurt A. Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists. Clin Pharmacol Ther. 2005 Dec;78(6):619-26. PubMed PMID: 16338277.

52: Cheirsilpa A, Sinthusake T, Songsakkaesorn A, Visawaprasit S, Chulaka K, Changkuingdee N. Comparison of ramosetron and granisetron for the prevention of acute and delayed emesis in Cisplatin-based chemotherapy: a randomized controlled trial. Jpn J Clin Oncol. 2005 Dec;35(12):695-9. Epub 2005 Nov 30. PubMed PMID: 16319109.

53: Pinarli FG, Elli M, Dagdemir A, Baysal K, Acar S. Electrocardiographic findings after 5-HT3 receptor antagonists and chemotherapy in children with cancer. Pediatr Blood Cancer. 2006 Oct 15;47(5):567-71. PubMed PMID: 16317736.

54: Aapro M, Rabaeus M. Re: The effects of ondansetron and granisetron on electrocardiography in children receiving chemotherapy for acute leukemia. Am J Clin Oncol. 2005 Dec;28(6):634-5. PubMed PMID: 16317278.

55: Kurnianda J, Hisyam B, Wahyuningsih E, Hutajulu SH. The efficacy of granisetron for cancer patients undergoing platinum-based chemotherapy: comparison of 1 miligram versus 3 miligram doses in preventing nausea and vomiting. Acta Med Indones. 2005 Oct-Dec;37(4):210-3. PubMed PMID: 16317218.

56: Kim SJ, Taguchi T, Miyoshi Y, Tanji Y, Tamaki Y, Noguchi S. [The feasibility of FEC (75) as adjuvant chemotherapy for Japanese breast cancer patients]. Gan To Kagaku Ryoho. 2005 Nov;32(12):1919-23. Japanese. PubMed PMID: 16282727.

57: Ikeda M, Yasui M, Fukunaga H, Seshimo I, Takayama O, Ikenaga M, Yamamoto H, Ohue M, Sekimoto M, Monden M. Clinical usefulness of oral granisetron hydrochloride for alleviation of delayed nausea and vomiting induced by CPT-11. Eur J Cancer Care (Engl). 2005 Dec;14(5):435-9. PubMed PMID: 16274464.

58: Holdsworth MT, Vo-Nguyen T. Employment of substandard antiemetic prophylaxis in recent trials of chemotherapy-induced nausea and vomiting. Ann Pharmacother. 2005 Nov;39(11):1903-10. Epub 2005 Oct 4. Review. PubMed PMID: 16204394.

59: Yamshita Y, Shikimori M, Goto M. [Clinical trial of chemotherapy by superselective intra-arterial infusion of nedaplatin combined with radiotherapy for advanced oral cancer]. Gan To Kagaku Ryoho. 2005 Sep;32(9):1267-71. Japanese. PubMed PMID: 16184922.

60: Olver IN. Update on anti-emetics for chemotherapy-induced emesis. Intern Med J. 2005 Aug;35(8):478-81. Review. PubMed PMID: 16176471.

61: Rubenstein EB. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol. 2004 May;2(5):284-9. Review. PubMed PMID: 16163194.

62: 5HT3-receptor antagonists as antiemetics in cancer. Drug Ther Bull. 2005 Aug;43(8):57-62. PubMed PMID: 16111085.

63: Abali H, Oyan B, Guler N. Alprazolam significantly improves the efficacy of granisetron in the prophylaxis of emesis secondary to moderately emetogenic chemotherapy in patients with breast cancer. Chemotherapy. 2005 Aug;51(5):280-5. Epub 2005 Aug 12. PubMed PMID: 16103667.

64: Nakayama H, Yamakuni H, Higaki M, Ishikawa H, Imazumi K, Matsuo M, Mutoh S. Antiemetic activity of FK1052, a 5-HT3- and 5-HT4-receptor antagonist, in Suncus murinus and ferrets. J Pharmacol Sci. 2005 Aug;98(4):396-403. Epub 2005 Jul 29. PubMed PMID: 16079468.

65: Feyer P, Seegenschmiedt MH, Steingraeber M. Granisetron in the control of radiotherapy-induced nausea and vomiting: a comparison with other antiemetic therapies. Support Care Cancer. 2005 Sep;13(9):671-8. Epub 2005 Jul 26. Review. PubMed PMID: 16044252.

66: Yano S, Makino K, Nakamura H, Kai Y, Morioka M, Hamada J, Kochi M, Kuratsu J. Comparative clinical study of the anti-emetic effects of oral ramosetron and injected granisetron in patients with malignant glioma undergoing ACNU chemotherapy. Neurol Med Chir (Tokyo). 2005 Jun;45(6):294-8; discussion 298-9. PubMed PMID: 15973062.

67: Aapro M, Blower P. 5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents? Cancer. 2005 Jul 1;104(1):1-18. Review. PubMed PMID: 15929119.

68: Tsukagoshi S; Tokyo Cooperative Oncology Group. [Introduction of novel anti-emetic agent, indisetron hydrochloride, developed recently in Japan]. Gan To Kagaku Ryoho. 2005 Apr;32(4):567-73. Review. Japanese. PubMed PMID: 15853230.

69: Moreno J, Sahade M, del Giglio A. Low-dose granisetron for prophylaxis of acute chemotherapy-induced nausea and vomiting: a pilot study. Support Care Cancer. 2005 Oct;13(10):850-3. Epub 2005 Apr 19. PubMed PMID: 15838618.

70: Buyukavci M, Olgun H, Ceviz N. The effects of ondansetron and granisetron on electrocardiography in children receiving chemotherapy for acute leukemia. Am J Clin Oncol. 2005 Apr;28(2):201-4. PubMed PMID: 15803017.

71: Bousquet PJ, Co-Minh HB, Demoly P. Isolated urticaria to ondansetron and successful treatment with granisetron. Allergy. 2005 Apr;60(4):543-4. PubMed PMID: 15727597.

72: Navari RM, Einhorn LH, Passik SD, Loehrer PJ Sr, Johnson C, Mayer ML, McClean J, Vinson J, Pletcher W. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer. 2005 Jul;13(7):529-34. Epub 2005 Feb 8. PubMed PMID: 15700131.

73: Mandalà M, Cremonesi M, Rocca A, Cazzaniga M, Ferretti G, Di Cosimo S, Ghilardi M, Cabiddu M, Barni S. Midazolam for acute emesis refractory to dexamethasone and granisetron after highly emetogenic chemotherapy: a phase II study. Support Care Cancer. 2005 Jun;13(6):375-80. Epub 2005 Jan 25. PubMed PMID: 15668754.

74: Jordan K, Grothey A, Kegel T, Fibich C, Schöbert C. Antiemetic efficacy of an oral suspension of granisetron plus dexamethasone and influence of quality of life on risk for nausea and vomiting. Onkologie. 2005 Feb;28(2):88-92. PubMed PMID: 15662112.

75: Dua N, Bhatnagar S, Mishra S, Singhal AK. Granisetron and ondansetron for prevention of nausea and vomiting in patients undergoing modified radical mastectomy. Anaesth Intensive Care. 2004 Dec;32(6):761-4. PubMed PMID: 15648984.

76: Aapro M. Granisetron: an update on its clinical use in the management of nausea and vomiting. Oncologist. 2004;9(6):673-86. Review. PubMed PMID: 15561811.

77: Gridelli C. Same old story? Do we need to modify our supportive care treatment of elderly cancer patients? Focus on antiemetics. Drugs Aging. 2004;21(13):825-32. Review. PubMed PMID: 15493948.

78: Dranitsaris G, Leung P. Using decision modeling to determine pricing of new pharmaceuticals: the case of neurokinin-1 receptor antagonist antiemetics for cancer chemotherapy. Int J Technol Assess Health Care. 2004 Summer;20(3):289-95. PubMed PMID: 15446758.

79: Goldsmith B. First choice for radiation-induced nausea and vomiting--the efficacy and safety of granisetron. Acta Oncol. 2004 Sep;43 Suppl 15:19-22. Review. PubMed PMID: 15370626.

80: Minami M, Endo T, Hamaue N, Hirafuji M. [Serotonin and anticancer drug-induced emesis]. Yakugaku Zasshi. 2004 Aug;124(8):491-507. Review. Japanese. PubMed PMID: 15297719.

81: Jaing TH, Tsay PK, Hung IJ, Yang CP, Hu WY. Single-dose oral granisetron versus multidose intravenous ondansetron for moderately emetogenic cyclophosphamide-based chemotherapy in pediatric outpatients with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2004 Apr-May;21(3):227-35. PubMed PMID: 15202162.

82: Tan M, Xu R, Seth R. Granisetron vs dolasetron for acute chemotherapy-induced nausea and vomiting (CINV) in high and moderately high emetogenic chemotherapy: an open-label pilot study. Curr Med Res Opin. 2004 Jun;20(6):879-82. PubMed PMID: 15200746.

83: Tralongo P, Dimari A, Conti G, Aiello R, Mauceri G. Central nervous system side-effects of 5-HT3-receptor antagonists in elderly cancer patients treated with chemotherapy. Ann Oncol. 2004 Jun;15(6):987-8. PubMed PMID: 15151959.

84: Dempsey CL, Coop AJ, Shillington A, Farley PA, Eberhardt DR, O'Briant S. Antiemetic effectiveness of ondansetron and granisetron in patients with breast cancer treated with cyclophosphamide. Am J Health Syst Pharm. 2004 Apr 15;61(8):781-6. PubMed PMID: 15127961.

85: Minegishi Y, Ohmatsu H, Miyamoto T, Niho S, Goto K, Kubota K, Kakinuma R, Kudoh S, Nishiwaki Y. Efficacy of droperidol in the prevention of cisplatin-induced delayed emesis: a double-blind, randomised parallel study. Eur J Cancer. 2004 May;40(8):1188-92. PubMed PMID: 15110882.

86: Lehoczky O, Udvary J, Bagaméri A, Pulay T. Does increasing the steroid dose enhance the efficacy of the antiemetic combination of granisetron and methylprednisolone in gynecologic cancer patients--a randomized study. Eur J Obstet Gynecol Reprod Biol. 2004 Mar 15;113(1):94-7. PubMed PMID: 15036719.

87: Porzio G, Aielli F, Narducci F, Cannita K, Piccolo D, Marchetti P. Pruritus in a patient with advanced cancer successfully treated with continuous infusion of granisetron. Support Care Cancer. 2004 Mar;12(3):208-9. Epub 2004 Jan 21. PubMed PMID: 14735336.

88: Russo M. [Re: Peter Blower's recent review of granisetron]. Support Care Cancer. 2004 Jan;12(1):64-5; author reply 66-8. Epub 2003 Dec 12. PubMed PMID: 14673627.

89: Koizumi W, Tanabe S, Nagaba S, Higuchi K, Nakayama N, Saigenji K, Nonaka M, Yago K. A double-blind, crossover, randomized comparison of granisetron and ramosetron for the prevention of acute and delayed cisplatin-induced emesis in patients with gastrointestinal cancer: is patient preference a better primary endpoint? Chemotherapy. 2003 Dec;49(6):316-23. PubMed PMID: 14671433.

90: Carmichael J, Harris AL. The cardiovascular safety of high-dose intravenous granisetron in cancer patients receiving highly emetogenic chemotherapy. Cancer Chemother Pharmacol. 2004 Feb;53(2):123-8. Epub 2003 Nov 22. PubMed PMID: 14634790.

91: Carmichael J, Harris AL. High-dose i.v. granisetron for the prevention of chemotherapy-induced emesis: cardiac safety and tolerability. Anticancer Drugs. 2003 Oct;14(9):739-44. PubMed PMID: 14551508.

92: Kelm-Kahl I. [Glucocorticoids: a two-edged sword in tumor therapy?]. Dtsch Med Wochenschr. 2003 Aug 15;128(33):1697. German. PubMed PMID: 12968629.

93: Gridelli C. 5-HT3-receptor antagonists in the control of delayed-onset emesis. Anticancer Res. 2003 May-Jun;23(3C):2773-82. Review. PubMed PMID: 12926112.

94: Navari RM, Koeller JM. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists. Ann Pharmacother. 2003 Sep;37(9):1276-86. Review. PubMed PMID: 12921512.

95: Feng F, Zhang P, He Y, Li Y, Zhou M, Chen G, Li L. Clinical comparison of the selective serotonin3 antagonists ramosetron and granisetron in treating acute chemotherapy-induced emesis, nausea and anorexia. Chin Med Sci J. 2002 Sep;17(3):168-72. PubMed PMID: 12901541.

96: Prentice HG. Granisetron in the control of nausea and vomiting associated with bone marrow transplantation: a review of its efficacy and tolerability. Support Care Cancer. 2003 Aug;11(8):501-8. Epub 2003 Jul 5. Review. PubMed PMID: 12845514.

97: Inoue A, Yamada Y, Matsumura Y, Shimada Y, Muro K, Gotoh M, Hamaguchi T, Mizuno T, Shirao K. Randomized study of dexamethasone treatment for delayed emesis, anorexia and fatigue induced by irinotecan. Support Care Cancer. 2003 Aug;11(8):528-32. Epub 2003 Jul 3. PubMed PMID: 12844250.

98: Fujii M. [Nausea and vomiting]. Nippon Rinsho. 2003 Jun;61(6):954-8. Review. Japanese. PubMed PMID: 12806942.

99: Minami M. Granisetron: is there a dose-response effect on nausea and vomiting? Cancer Chemother Pharmacol. 2003 Aug;52(2):89-98. Epub 2003 May 29. Review. PubMed PMID: 12783208.

100: Lachaine J, Crott R. Cost-effectiveness of antiemetics use during cancer chemotherapy. Expert Rev Pharmacoecon Outcomes Res. 2003 Jun;3(3):263-72. PubMed PMID: 19807374.

101: Hesketh PJ, Van Belle S, Aapro M, Tattersall FD, Naylor RJ, Hargreaves R, Carides AD, Evans JK, Horgan KJ. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer. 2003 May;39(8):1074-80. PubMed PMID: 12736106.

102: Aapro M, Bourke JP. Rapid intravenous administration of granisetron prior to chemotherapy is not arythmogenic: results of a pilot study. Eur J Cancer. 2003 May;39(7):927-31. PubMed PMID: 12706361.

103: Wang YJ, Cheng ZG, Guo QL. [Clinical observation of granisetron in preventing postoperative nausea and vomiting following supratentorial craniotomy]. Hunan Yi Ke Da Xue Xue Bao. 2002 Dec 28;27(6):545-6. Chinese. PubMed PMID: 12658936.

104: Aapro MS, Thuerlimann B, Sessa C, De Pree C, Bernhard J, Maibach R; Swiss Group for Clinical Cancer Research. A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis. Ann Oncol. 2003 Feb;14(2):291-7. PubMed PMID: 12562658.

105: Blower PR. Granisetron: relating pharmacology to clinical efficacy. Support Care Cancer. 2003 Feb;11(2):93-100. Epub 2002 Nov 15. Review. PubMed PMID: 12560937.

106: Numbenjapon T, Sriswasdi C, Mongkonsritragoon W, Leelasiri A, Prayoonwiwat W. Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma. J Med Assoc Thai. 2002 Nov;85(11):1156-63. PubMed PMID: 12546311.

107: Zhang P, Feng F, He Y, Li Y, Zhou M, Cheng G, Chen Y. [Nausea disintegrating buccal tablet in the prevention of gastrointestinal reaction induced by anticancer drugs]. Zhonghua Zhong Liu Za Zhi. 2002 Sep;24(5):504-7. Chinese. PubMed PMID: 12485511.

108: Sagae S, Ishioka S, Fukunaka N, Terasawa K, Kobayashi K, Sugimura M, Nishioka Y, Kudo R, Minami M. Combination therapy with granisetron, methylprednisolone and droperidol as an antiemetic prophylaxis in CDDP-induced delayed emesis for gynecologic cancer. Oncology. 2003;64(1):46-53. PubMed PMID: 12457031.

109: Longfield V. Compatibility and stability of 5-HT3 receptor antagonists: a pharmacology review. Oncol Nurs Forum. 2002 Nov-Dec;29(10):1469-82. Review. PubMed PMID: 12432417.

110: Blower PR. 5-HT3-receptor antagonists and the cytochrome P450 system: clinical implications. Cancer J. 2002 Sep-Oct;8(5):405-14. Review. PubMed PMID: 12416899.

111: Behnam-Motlagh P, Sandström PE, Henriksson R, Grankvist K. Ondansetron but not granisetron affect cell volume regulation and potassium ion transport of glioma cells treated with estramustine phosphate. J Cancer Res Clin Oncol. 2002 Aug;128(8):449-55. Epub 2002 Aug 10. PubMed PMID: 12200602.

112: Markman M. Progress in preventing chemotherapy-induced nausea and vomiting. Cleve Clin J Med. 2002 Aug;69(8):609-10, 612, 615-7. Review. PubMed PMID: 12184469.

113: Kang YK, Park YH, Ryoo BY, Bang YJ, Cho KS, Shin DB, Kim HC, Lee KH, Park YS, Lee KS, Heo DS, Kim SY, Cho EK, Lim HY, Kim WK, Lee JA, Kim TY, Lee JC, Yoon HJ, Kim NK. Ramosetron for the prevention of cisplatin-induced acute emesis: a prospective randomized comparison with granisetron. J Int Med Res. 2002 May-Jun;30(3):220-9. PubMed PMID: 12166338.

114: Markman MR, Peterson G, Kulp B, Markman M. Effectiveness of serotonin-receptor antagonist antiemetic therapy over successive courses of carboplatin-based chemotherapy. Gynecol Oncol. 2002 Jun;85(3):435-7. PubMed PMID: 12051870.

115: Mikawa K, Akamatsu H, Nishina K, Shiga M, Niwa Y. Effects of ondansetron, granisetron, ramosetron, and azasetron on human neutrophil functions. Gynecol Obstet Invest. 2002;53(2):93-9. PubMed PMID: 11961382.

116: Keefe DL. The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern? Oncologist. 2002;7(1):65-72. Review. PubMed PMID: 11854548.

117: Togo S, Akiyama H, Yamaguchi S, Ichikawa Y, Ike H, Shimada H. Clinical evaluation of granisetron as an inhibitor of nausea and vomiting induced by oral anticancer drugs. Oncol Rep. 2002 Mar-Apr;9(2):277-82. PubMed PMID: 11836592.

118: Watters J, Riley M, Pedley I, Whitehead A, Overend M, Goss I, Allgar V. The development of a protocol for the use of 5-HT3 antagonists in chemotherapy-induced nausea and vomiting. Clin Oncol (R Coll Radiol). 2001;13(6):422-6. PubMed PMID: 11824878.

119: Wang J, Yang L, Cui C. [The clinical effect of Tropisetron in the prevention of nausea and vomiting induced by anti-cancer drugs]. Zhonghua Zhong Liu Za Zhi. 2001 May;23(3):251-3. Chinese. PubMed PMID: 11783100.

120: Zhang P, Feng F, He Y. [Nasea injection in the prophylaxis of gastrointestinal reaction induced by chemotherapeutic agents]. Zhonghua Zhong Liu Za Zhi. 2000 Jan;22(1):70-3. Chinese. PubMed PMID: 11776606.

121: Lanciano R, Sherman DM, Michalski J, Preston AJ, Yocom K, Friedman C. The efficacy and safety of once-daily Kytril (granisetron hydrochloride) tablets in the prophylaxis of nausea and emesis following fractionated upper abdominal radiotherapy. Cancer Invest. 2001;19(8):763-72. PubMed PMID: 11768028.

122: Dranitsaris G, Leung P, Warr D. Implementing evidence based antiemetic guidelines in the oncology setting: results of a 4-month prospective intervention study. Support Care Cancer. 2001 Nov;9(8):611-8. PubMed PMID: 11762972.

123: Mochiki E, Nakabayashi T, Suzuki H, Haga N, Fujita K, Asao T, Kuwano H. Barostat examination of proximal site of the anastomosis in patients with rectal cancer after low anterior resection. World J Surg. 2001 Nov;25(11):1377-82. PubMed PMID: 11760737.

124: Tsukada H, Hirose T, Yokoyama A, Kurita Y. Randomised comparison of ondansetron plus dexamethasone with dexamethasone alone for the control of delayed cisplatin-induced emesis. Eur J Cancer. 2001 Dec;37(18):2398-404. PubMed PMID: 11720834.

125: de Wit R, de Boer AC, vd Linden GH, Stoter G, Sparreboom A, Verweij J. Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer. 2001 Oct 19;85(8):1099-101. PubMed PMID: 11710819; PubMed Central PMCID: PMC2375154.

126: Lehoczky O, Bagaméri A, Sárosi Z, Kulcsár T, Pulay T. [Does the addition of an anxiolytic drug improve the anti-emetic effectiveness of the steroid and granisetron combination in the prophylaxis of cisplatin-induced vomiting?]. Orv Hetil. 2001 Aug 5;142(31):1681-4. Hungarian. PubMed PMID: 11556262.

127: Aksoylar S, Akman SA, Ozgenç F, Kansoy S. Comparison of tropisetron and granisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy. Pediatr Hematol Oncol. 2001 Sep;18(6):397-406. PubMed PMID: 11554235.

128: Nakayama S, Torii Y, Noda T. [Evaluation of efficacy of ramosetron orally disintegrating tablets and patient preference as to the dosage form in gynecological cancer chemotherapy]. Gan To Kagaku Ryoho. 2001 Aug;28(8):1121-7. Japanese. PubMed PMID: 11525029.

129: Fujii M, Ohno Y, Tokumaru Y, Imanishi Y, Kanke M, Tomita T, Kanzaki J. Manifest Anxiety Scale for evaluation of effects of granisetron in chemotherapy with CDDP and 5FU for head and neck cancer. Support Care Cancer. 2001 Jul;9(5):366-71. PubMed PMID: 11497391.

130: Goram AL, Richmond PL. Pegylated liposomal doxorubicin: tolerability and toxicity. Pharmacotherapy. 2001 Jun;21(6):751-63. PubMed PMID: 11401188.

131: Behnam-Motlagh P, Sandström PE, Henriksson R, Grankvist K. Diverging effects of 5-HT3 receptor antagonists ondansetron and granisetron on estramustine-inhibited cellular potassium transport. Pharmacol Toxicol. 2001 May;88(5):244-9. PubMed PMID: 11393584.

132: Fujii Y, Tanaka H, Kawasaki T. Preoperative oral granisetron for the prevention of postoperative nausea and vomiting after breast surgery. Eur J Surg. 2001 Mar;167(3):184-7. PubMed PMID: 11316402.

133: Wada I, Takeda T, Sato M, Saitoh H, Nakabayashi T, Mino K, Honma T, Takada M, Hirano K. Pharmacokinetics of granisetron in adults and children with malignant diseases. Biol Pharm Bull. 2001 Apr;24(4):432-5. PubMed PMID: 11305610.

134: Campos D, Pereira JR, Reinhardt RR, Carracedo C, Poli S, Vogel C, Martinez-Cedillo J, Erazo A, Wittreich J, Eriksson LO, Carides AD, Gertz BJ. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol. 2001 Mar 15;19(6):1759-67. PubMed PMID: 11251007.

135: Walton SM. Advances in use of the 5-HT3 receptor antagonists. Expert Opin Pharmacother. 2000 Jan;1(2):207-23. Review. PubMed PMID: 11249543.

136: del Giglio A, Soares HP, Caparroz C, Castro PC. Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials. Cancer. 2000 Dec 1;89(11):2301-8. PubMed PMID: 11147601.

137: Lacerda JF, Martins C, Carmo JA, Lourenço MF, Araújo Pereira ME, Rodrigues A, Juncal C, Lacerda JM. Randomized trial of ondansetron, granisetron, and tropisetron in the prevention of acute nausea and vomiting. Transplant Proc. 2000 Dec;32(8):2680-1. PubMed PMID: 11134761.

138: Slabý J, Trnený M, Procházka B, Klener P. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma. Neoplasma. 2000;47(5):319-22. PubMed PMID: 11130251.

139: Chiou TJ, Tzeng WF, Wang WS, Yen CC, Fan FS, Liu JH, Chen PM. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy. Zhonghua Yi Xue Za Zhi (Taipei). 2000 Oct;63(10):729-36. PubMed PMID: 11076429.

140: Vermeulen LC, Windisch PA, Rydman RJ, Bruskiewitz RH, Brixner DI, Vlasses PH. Using a multihospital systems framework to evaluate and establish drug use policy. J Med Syst. 2000 Aug;24(4):235-46. PubMed PMID: 11057402.

141: Togo S, Kunisaki C, Moriwaki Y, Yamaguchi S, Ichikawa Y, Oki S, Shimada H, Takahashi M, Ike H, Fukushima T, Obi Y, Kubo A, Takahashi T, Hosoi H, Fukazawa S, Suda T, Yamazaki Y. [Clinical evaluation of granisetron hydrochloride for nausea and vomiting induced by oral anticancer drugs]. Gan To Kagaku Ryoho. 2000 Jul;27(7):1021-8. Japanese. PubMed PMID: 10925688.

142: Barrajon E, de las Peñas R. Randomised double blind crossover study comparing ondansetron, granisetron and tropisetron. A cost-benefit analysis. Support Care Cancer. 2000 Jul;8(4):323-33. PubMed PMID: 10923774.

143: McClay EF, McClay ME, Monroe L, Baron PL, Cole DJ, O'Brien PH, Metcalf JS, Maize JC. The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma. Br J Cancer. 2000 Jul;83(1):16-21. PubMed PMID: 10883662; PubMed Central PMCID: PMC2374536.

144: Hesketh PJ, Crews JR, Cohen R, Blackburn LM, Friedman CJ. Antiemetic efficacy of single-dose oral granisetron (1 mg vs 2 mg) with moderately emetogenic chemotherapy. Cancer J. 2000 May-Jun;6(3):157-61. PubMed PMID: 10882331.

145: Abbott B, Ippoliti C, Hecth D, Bruton J, Whaley B, Champlin R. Granisetron (Kytril) plus dexamethasone for antiemetic control in bone marrow transplant patients receiving highly emetogenic chemotherapy with or without total body irradiation. Bone Marrow Transplant. 2000 Jun;25(12):1279-83. PubMed PMID: 10871733.

146: Saleh MN, Sugarman S, Murray J, Ostroff JB, Healey D, Jones D, Daniel CR, LeBherz D, Brewer H, Onetto N, LoBuglio AF. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. J Clin Oncol. 2000 Jun;18(11):2282-92. PubMed PMID: 10829049.

147: Friedman CJ, Burris HA 3rd, Yocom K, Blackburn LM, Gruben D. Oral granisetron for the prevention of acute late onset nausea and vomiting in patients treated with moderately emetogenic chemotherapy. Oncologist. 2000;5(2):136-43. PubMed PMID: 10794804.

148: Ishioka S, Sagae S, Saito T, Kiya T, Sugimura M, Akutagawa N, Umemura K, Ito E, Kudo R. [Effects of oral 5-HT3 antagonists on chemotherapy-induced emesis in patients with gynecologic cancers]. Gan To Kagaku Ryoho. 2000 Apr;27(4):593-8. Japanese. PubMed PMID: 10791002.

149: Sigsgaard T, Herrstedt J, Christensen P, Andersen O, Dombernowsky P. Antiemetic efficacy of combination therapy with granisetron plus prednisolone plus the dopamine D2 antagonist metopimazine during multiple cycles of moderately emetogenic chemotherapy in patients refractory to previous antiemetic therapy. Support Care Cancer. 2000 May;8(3):233-7. PubMed PMID: 10789966.

150: Anastasia PJ. Effectiveness of oral 5-HT3 receptor antagonists for emetogenic chemotherapy. Oncol Nurs Forum. 2000 Apr;27(3):483-93. Review. PubMed PMID: 10785902.

151: Chua DT, Sham JS, Kwong DL, Kwok CC, Yue A, Foo YC, Chan R. Comparative efficacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: a randomized crossover study. Am J Clin Oncol. 2000 Apr;23(2):185-91. PubMed PMID: 10776982.

152: Oge A, Alkiş N, Oge O, Kartum A. Comparison of granisetron, ondansetron and tropisetron for control of vomiting and nausea induced by cisplatin. J Chemother. 2000 Feb;12(1):105-8. PubMed PMID: 10768522.

153: Inoue S, Endo K, Suzuki H, Endo K. [Anti-emetic treatment for patients with lung cancer after chemotherapy, and usefulness of prochlorperazine for psychiatric emesis]. Gan To Kagaku Ryoho. 2000 Mar;27(3):405-11. Japanese. PubMed PMID: 10740634.

154: Forni C, Ferrari S, Loro L, Mazzei T, Beghelli C, Biolchini A, Simoni P, Tremosini M, Strazzari S, Puggioli C, Bacci G. Granisetron, tropisetron, and ondansetron in the prevention of acute emesis induced by a combination of cisplatin-Adriamycin and by high-dose ifosfamide delivered in multiple-day continuous infusions. Support Care Cancer. 2000 Mar;8(2):131-3. PubMed PMID: 10739360.

155: Hesketh PJ, Roman A, Hesketh AM, Perez EA, Edelman M, Gandara DR. Control of high-dose-cisplatin-induced emesis with an all-oral three-drug antiemetic regimen. Support Care Cancer. 2000 Jan;8(1):46-8. PubMed PMID: 10650897.

156: Yamauchi H, Ishikawa H, Suzuki S, Nagaji M, Fujiwara K, Kohno I. [Optimal timing of granisetron administration for the prevention of carboplatin-induced acute emesis]. Gan To Kagaku Ryoho. 1999 Dec;26(14):2217-21. Japanese. PubMed PMID: 10635307.

157: Perez EA. 5-HT3 antiemetic therapy for patients with breast cancer. Breast Cancer Res Treat. 1999 Sep;57(2):207-14. Review. PubMed PMID: 10598048.

158: Fujii M, Kanke M, Tomita T. [Low-dose CDDP and 5-FU for head and neck cancer patients]. Gan To Kagaku Ryoho. 1999 Oct;26(11):1542-7. Japanese. PubMed PMID: 10553410.

159: Drapkin R, Barolo JL, Blower PR. Effect of granisetron on performance status during high-dose interferon therapy. Oncology. 1999 Nov;57(4):303-5. PubMed PMID: 10575316.

160: Shanahan F, O'Sullivan GC. Neurokinin antagonism and chemotherapy-induced emesis. Am J Gastroenterol. 1999 Nov;94(11):3368-9. PubMed PMID: 10566748.

161: Castejon AM, Paez X, Hernandez L, Cubeddu LX. Use of intravenous microdialysis to monitor changes in serotonin release and metabolism induced by cisplatin in cancer patients: comparative effects of granisetron and ondansetron. J Pharmacol Exp Ther. 1999 Dec;291(3):960-6. PubMed PMID: 10565811.

162: Komada Y, Matsuyama T, Takao A, Hongo T, Nishimura Y, Horibe K, Sakurai M. A randomised dose-comparison trial of granisetron in preventing emesis in children with leukaemia receiving emetogenic chemotherapy. Eur J Cancer. 1999 Jul;35(7):1095-101. PubMed PMID: 10533454.

163: Sawada T, Matsumura T, Mugishima H, Kaneko M, Ohira M, Sugimoto T, Onuma N, Sakurai M, Takeda T. [Clinical evaluation of granisetron (BRL43694) in nausea and vomiting induced by anticancer drugs--pediatrics]. Gan To Kagaku Ryoho. 1999 Aug;26(9):1295-304. Japanese. PubMed PMID: 10478183.

164: Hesketh PJ, Gralla RJ, Webb RT, Ueno W, DelPrete S, Bachinsky ME, Dirlam NL, Stack CB, Silberman SL. Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis. J Clin Oncol. 1999 Jan;17(1):338-43. PubMed PMID: 10458252.

165: Bauduer F, Coiffier B, Desablens B. Granisetron plus or minus alprazolam for emesis prevention in chemotherapy of lymphomas: a randomized multicenter trial. Granisetron Trialists Group. Leuk Lymphoma. 1999 Jul;34(3-4):341-7. PubMed PMID: 10439371.

166: Ono K, Uchida I, Uno N, Ohno E, Hirota K, Nakayama T, Ohtuka E, Saburi Y, Kikuchi H, Nasu M. [Efficacy of combination with granisetron and methylprednisolone for nausea, vomiting and appetite loss in remission induction chemotherapy of acute myeloid leukemia--a randomized comparative trial between granisetron alone and granisetron plus methylprednisolone]. Gan To Kagaku Ryoho. 1999 May;26(6):821-8. Japanese. PubMed PMID: 10410152.

167: Inoue S, Endo K, Ichimura H, Endo K. [Anti-emetic treatment for patients with non-small cell lung cancer after chemotherapy, usefulness of preventive combination of anti-emetic agents and importance of psychiatric aspect of patients]. Gan To Kagaku Ryoho. 1999 May;26(6):813-9. Japanese. PubMed PMID: 10410151.

168: Sigsgaard T, Herrstedt J, Andersen LJ, Havsteen H, Langer SW, Kjaerbøl AG, Lund H, Kjaer M, Dombernowsky P. Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy. Br J Cancer. 1999 May;80(3-4):412-8. PubMed PMID: 10408847; PubMed Central PMCID: PMC2362348.

169: Tsukagoshi S. [Pharmacokinetics of azasetron (Serotone), a selective 5-HT3 receptor antagonist]. Gan To Kagaku Ryoho. 1999 Jun;26(7):1001-8. Japanese. PubMed PMID: 10396331.

170: Behnam-Motlagh P, Engström KG, Henriksson R, Grankvist K. Serotoninergic modulation of cell volume response to estramustine: an image-analysis study on perifused individual glioma cells. Eur J Cancer. 1999 Jan;35(1):145-53. PubMed PMID: 10211103.

171: Mabro M, Granisétron PK. [Comparative trial of oral granisetron and intravenous ondansetron in patients receiving chemotherapy for breast cancer. Study Group of Granisetron]. Bull Cancer. 1999 Mar;86(3):295-301. French. PubMed PMID: 10210764.

172: Tatsumi N, Masaoka T. A comparative study of administration methods of granisetron injection used to treat nausea/vomiting induced by cancer chemotherapy without cisplatin in tumors of hematopoietic organs. Keihanshin Study Group of Hematological Malignancies. Cancer Chemother Pharmacol. 1999;43(5):379-84. PubMed PMID: 10100592.

173: Uchida K, Akaza H, Hattori K, Noguchi R, Kondo F, Ishikawa S, Ohtani M, Hinotsu S, Koiso K. Antiemetic efficacy of granisetron: a randomized crossover study in patients receiving cisplatin-containing intraarterial chemotherapy. Jpn J Clin Oncol. 1999 Feb;29(2):87-91. PubMed PMID: 10089949.

174: Tsuchida Y, Hayashi Y, Asami K, Yamamoto K, Yokoyama J, Mugishima H, Honna T, Mimaya J, Hara F, Sawada T, Matsumura T, Suita S, Sugimoto T, Kaneko M. Effects of granisetron in children undergoing high-dose chemotherapy: a multi-institutional, cross-over study. Int J Oncol. 1999 Apr;14(4):673-9. PubMed PMID: 10087313.

175: Abbott B, Ippoliti C, Bruton J, Neumann J, Whaley R, Champlin R. Antiemetic efficacy of granisetron plus dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation. Bone Marrow Transplant. 1999 Feb;23(3):265-9. PubMed PMID: 10084258.

176: Sawaguchi K, Yabushita H, Tsukada H, Yamada H, Noguchi M, Nakanishi M. [Clinical studies of oral antiemetic drugs on delayed emesis induced by cancer chemotherapy]. Gan To Kagaku Ryoho. 1999 Jan;26(1):117-23. Japanese. PubMed PMID: 9987507.

177: Lehoczky O. Report on the antiemetic effectivity of a single 1 mg oral granisetron in moderately emetogenic chemotherapies of gynecological malignancies. Eur J Gynaecol Oncol. 1998;19(5):449-52. PubMed PMID: 9863909.

178: Brown RS, Brown TK, Hoare D, Gaze MN. An audit of antiemetic use with CMF chemotherapy. Clin Oncol (R Coll Radiol). 1998;10(5):313-7. PubMed PMID: 9848332.

179: Satoh Y, Oshima T, Takahashi N, Ogawa H, Shiroto H, Akasaka Y, Nakanishi Y, Uchino J, Koshino I, Une Y, Todo S. [Comparison of crossing-over between 30-minute drip infusion vs 30-second injection of granisetron for nausea and vomitting with cisplatin]. Gan To Kagaku Ryoho. 1998 Nov;25(13):2101-8. Japanese. PubMed PMID: 9838913.

180: Takeyama H, Miyata Y, Yamamoto Y, Saito M, Yamada H. [Efficacy of granisetron in the prevention of emesis induced by conditioning chemotherapy for allogeneic bone marrow transplantation]. Gan To Kagaku Ryoho. 1998 Nov;25(13):2095-9. Japanese. PubMed PMID: 9838912.

181: Birch R, Weaver CH, Carson K, Buckner CD. A randomized trial of once vs twice daily administration of intravenous granisetron with dexamethosone in patients receiving high-dose cyclophosphamide, thiotepa and carboplatin. Bone Marrow Transplant. 1998 Oct;22(7):685-8. PubMed PMID: 9818697.

182: Ikeda H, Koshiba R. [Comparison of antiemetic efficacy of granisetron as premedication versus combination therapy of granisetron]. Gan To Kagaku Ryoho. 1998 Oct;25(12):1947-53. Japanese. PubMed PMID: 9797818.

183: Ichida T, Isokawa O, Itoh S, Ohta H, Takagi K, Hatakeyama S, Tsuruya T, Doya Y, Nozawa A, Hata K, Hara H, Hirose S, Watanabe T, Asakura H. [Efficacy of granisetron as anti-emetic agent for emesis induced by intra-arterial injection therapy for hepatocellular carcinoma]. Gan To Kagaku Ryoho. 1998 Oct;25(12):1939-46. Japanese. PubMed PMID: 9797817.

184: Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Low-dose oral granisetron (1 mg) plus intravenous dexamethasone: efficacy in gynecologic cancer patients receiving carboplatin-based chemotherapy. Gynecol Oncol. 1998 Oct;71(1):113-5. PubMed PMID: 9784330.

185: Tsudo M, Moriguchi T. [Efficacy and safety of two methods of administration of granisetron injection for nausea and vomiting induced by chemotherapy for tumors in hematopoietic organs--a randomized crossover comparison between intravenous drip infusion and intravenous bolus injection]. Gan To Kagaku Ryoho. 1998 Sep;25(11):1747-53. Japanese. PubMed PMID: 9757201.

186: Martoni A, Piana E, Strocchi E, Angelelli B, Guaraldi M, Zamagni C, Camaggi CM, Pannuti F. Comparative crossover trial of two intravenous doses of granisetron (1 mg vs 3 mg) + dexamethasone in the prevention of acute cis-platinum-induced emesis. Anticancer Res. 1998 Jul-Aug;18(4B):2799-803. PubMed PMID: 9713464.

187: Zeidman A, Ben Dayan D, Ben Zion T, Kaufman O, Cohen AM, Mittelman M. Granisetron and ondansetron for chemotherapy-related nausea and vomiting. Haematologia (Budap). 1998;29(1):25-31. PubMed PMID: 9704254.

188: Kleisbauer JP, García-Girón C, Antimi M, Azevedo MC, Balmes H, Massuti-Sureda B, Contu A, Luque A, Pellier P. Granisetron plus methylprednisolone for the control of high-dose cisplatin-induced emesis. Anticancer Drugs. 1998 Jun;9(5):387-92. PubMed PMID: 9660534.

189: Carmichael J, Keizer HJ, Cupissol D, Milliez J, Scheidel P, Schindler AE. Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs. 1998 Jun;9(5):381-5. PubMed PMID: 9660533.

190: de Wit R, van den Berg H, Burghouts J, Nortier J, Slee P, Rodenburg C, Keizer J, Fonteyn M, Verweij J, Wils J. Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles. Br J Cancer. 1998 May;77(9):1487-91. PubMed PMID: 9652766; PubMed Central PMCID: PMC2150181.

191: Poon RT, Chow LW. Comparison of antiemetic efficacy of granisetron and ondansetron in Oriental patients: a randomized crossover study. Br J Cancer. 1998 May;77(10):1683-5. PubMed PMID: 9635849; PubMed Central PMCID: PMC2150069.

192: Kalaycio M, Mendez Z, Pohlman B, Overmoyer B, Boparai N, Jones E, Bolwell B. Continuous-infusion granisetron compared to ondansetron for the prevention of nausea and vomiting after high-dose chemotherapy. J Cancer Res Clin Oncol. 1998;124(5):265-9. PubMed PMID: 9645457.

193: Trovato JA, Stull DM, Finley RS. Outcomes of antiemetic therapy after the administration of high-dose antineoplastic agents. Am J Health Syst Pharm. 1998 Jun 15;55(12):1269-74. PubMed PMID: 9640466.

194: Wada I, Satoh M, Takeda T, Nakabayashi T, Honma T, Saitoh H, Takada M, Hirano K. A rapid assay of granisetron in biological fluids from cancer patients. Biol Pharm Bull. 1998 May;21(5):535-7. PubMed PMID: 9635515.

195: Climent MA, Palau J, Ruiz A, Soriano V, Aznar E, Olmos T, Guillem V. The antiemetic efficacy of granisetron plus dexamethasone, haloperidol and loracepam in breast cancer patients treated with high-dose chemotherapy with peripheral blood stem-cell support. Support Care Cancer. 1998 May;6(3):287-90. PubMed PMID: 9629884.

196: Tanaka K, Sekine M, Serikawa T, Sanada H, Shichiri K, Fujimori R. [Combination effect of granisetron plus corticosteroid for prevention of cisplatin-induced emesis: a cross-over study comparing methylprednisolone and dexamethasone]. Gan To Kagaku Ryoho. 1998 May;25(6):907-13. Japanese. PubMed PMID: 9617330.

197: Tzekova VI, Velikova MT, Koynov KD. Granisetron in repeated cycles of chemotherapy with platinum. Neoplasma. 1998;45(1):46-9. PubMed PMID: 9605002.

198: Sasai Y, Misawa S, Iwai T, Tamura A, Nakazawa N, Ueda Y, Kaneko H, Horiike S, Yokota S, Taniwaki M, Kashima K, Tsuda S, Ookawara Y, Nakao M, Nakagawa H, Fujii H. [Clinical study on the inhibitory effect of a 5-HT3 antagonist, granisetron, for nausea and vomiting induced by chemotherapy (CHOP, VEPA, high-dose ETP) for non-Hodgkin's lymphoma]. Gan To Kagaku Ryoho. 1998 Apr;25(5):723-9. Japanese. PubMed PMID: 9571970.

199: Gralla RJ, Navari RM, Hesketh PJ, Popovic W, Strupp J, Noy J, Einhorn L, Ettinger D, Bushnell W, Friedman C. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol. 1998 Apr;16(4):1568-73. PubMed PMID: 9552067.

200: Nakahara K, Minami M, Yasumitsu T, Ikeda M, Ohta M, Nakamura K, Akashi A, Kido T. [Effect of granisetron in preventing emesis due to anti-cancer drug (CDDP) administration pulmo-mediastinal malignancies--comparison of simultaneous infusion with the conventional method of administration]. Gan To Kagaku Ryoho. 1998 Mar;25(4):571-6. Japanese. PubMed PMID: 9530364.

201: Fujii Y, Tanaka H, Toyooka H. Prevention of nausea and vomiting in female patients undergoing breast surgery: a comparison with granisetron, droperidol, metoclopramide and placebo. Acta Anaesthesiol Scand. 1998 Feb;42(2):220-4. PubMed PMID: 9509207.

202: Latreille J, Pater J, Johnston D, Laberge F, Stewart D, Rusthoven J, Hoskins P, Findlay B, McMurtrie E, Yelle L, Williams C, Walde D, Ernst S, Dhaliwal H, Warr D, Shepherd F, Mee D, Nishimura L, Osoba D, Zee B. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1998 Mar;16(3):1174-8. PubMed PMID: 9508205.

203: Gregory RE, Ettinger DS. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs. 1998 Feb;55(2):173-89. Review. PubMed PMID: 9506240.

204: Nolte MJ, Berkery R, Pizzo B, Baltzer L, Grossano D, Lucarelli CD, Kris MG. Assuring the optimal use of serotonin antagonist antiemetics: the process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center. J Clin Oncol. 1998 Feb;16(2):771-8. PubMed PMID: 9469369.

205: Perez EA, Lembersky B, Kaywin P, Kalman L, Yocom K, Friedman C. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy. Cancer J Sci Am. 1998 Jan-Feb;4(1):52-8. PubMed PMID: 9467047.

206: Handberg J, Wessel V, Larsen L, Herrstedt J, Hansen HH. Randomized, double-blind comparison of granisetron versus granisetron plus prednisolone as antiemetic prophylaxis during multiple-day cisplatin-based chemotherapy. Support Care Cancer. 1998 Jan;6(1):63-7. PubMed PMID: 9458539.

207: Mantovani G, Macciò A, Curreli L, Lampis B, Ghiani M, Bianchi A, Contu P. Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin. Oncol Rep. 1998 Jan-Feb;5(1):273-80. PubMed PMID: 9458381.

208: Du Bois A. [Management of chemotherapy-induced emesis: what is the standard after 20 years of clinical research]. Med Klin (Munich). 1998 Jan;93 Suppl 1:3-17. Review. German. PubMed PMID: 19479418.

209: Park JO, Rha SY, Yoo NC, Kim JH, Roh JK, Min JS, Kim BS, Chung HC. A comparative study of intravenous granisetron versus intravenous and oral ondansetron in the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy. Am J Clin Oncol. 1997 Dec;20(6):569-72. PubMed PMID: 9391542.

210: Farley PA, Dempsey CL, Shillington AA, Kulis-Robitaille C, Colgan K, Bernstein G. Patients' self-reported functional status after granisetron or ondansetron therapy to prevent chemotherapy-induced nausea and vomiting at six cancer centers. Am J Health Syst Pharm. 1997 Nov 1;54(21):2478-82. PubMed PMID: 9359954.

211: Frakes LA, Brehm TL, Kosty MP, Miller WE, McMillan RL, Mason J, Meisenberg BR. An all oral antiemetic regimen for patients undergoing high-dose chemotherapy with peripheral blood stem cell transplant. Bone Marrow Transplant. 1997 Sep;20(6):473-8. PubMed PMID: 9313880.

212: Cunningham RS. 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy. Oncol Nurs Forum. 1997 Aug;24(7 Suppl):33-40. Review. PubMed PMID: 9282379.

213: Sharma SS, Kochupillai V, Gupta SK, Seth SD, Gupta YK. Antiemetic efficacy of ginger (Zingiber officinale) against cisplatin-induced emesis in dogs. J Ethnopharmacol. 1997 Jul;57(2):93-6. PubMed PMID: 9254112.

214: Yoshiya N, Kodama S, Aoki Y, Takahashi T, Honma S, Endo M, Tokunaga A, Takeuchi Y, Hanaoka J, Maruhashi T, Oshima T, Tanaka K, Furue H. [Clinical evaluation of 2-mg granisetron tablet for nausea and vomiting induced by anticancer drugs including cisplatin]. Gan To Kagaku Ryoho. 1997 Jul;24(9):1141-7. Japanese. PubMed PMID: 9239168.

215: Fujii M, Ohno Y, Tokumaru Y, Imanishi Y, Kanke M, Kanzaki J. [Comparison of effects between single vs five-day injection of granisetron for combination chemotherapy with cisplatin and 5-fluorouracil for head and neck cancer]. Gan To Kagaku Ryoho. 1997 Jul;24(9):1095-101. Japanese. PubMed PMID: 9239162.

216: Delayed emesis induced by moderately emetogenic chemotherapy: do we need to treat all patients? The Italian Group for Antiemetic Research. Ann Oncol. 1997 Jun;8(6):561-7. PubMed PMID: 9261525.

217: Takada M, Furuse K, Fukuoka M, Kawahara M, Negoro S, Kusunoki Y, Ogawara M, Furue H. [Clinical evaluation of 2 mg granisetron tablet for nausea and vomiting induced by anticancer drugs including cisplatin]. Gan To Kagaku Ryoho. 1997 Jun;24(8):987-94. Japanese. PubMed PMID: 9212809.

218: Wataba K, Sagae S, Fukunaka N, Sugimura M, Akutagawa N, Hayashi T, Yamana K, Nakamura T, Terasawa K, Mizumoto H, Kitajima Y, Kudo R. [A randomized cross-over comparative study of granisetron alone and combination of granisetron, methylprednisolone and droperidol as antiemetic prophilaxis in CDDP-based chemotherapy for gynecologic cancer]. Gan To Kagaku Ryoho. 1997 Apr;24(6):691-7. Japanese. PubMed PMID: 9126306.

219: Sismondi P, Danese S, Giardina G, Guercio E, Richiardi G, Carnino F, Ferraris C, Lissoni A, Inganni P, Maggi R, Boccardo E, Barbieri P. Antiemetic efficacy of granisetron in patients with gynecological malignancies. Anticancer Drugs. 1997 Mar;8(3):225-30. PubMed PMID: 9095326.

220: Park Y, Hatano Y, Sasamoto S, Kato N, Okuyama N, Yamazaki S. [Antiemetic efficacy of granisetron in repeated CAF chemotherapy after breast cancer operation]. Gan To Kagaku Ryoho. 1997 Mar;24(5):573-7. Japanese. PubMed PMID: 9087290.

221: Chang CS, Chen LT, Huang SM, Liu TC, Lin SF, Chen TP, Wei TC. Comparison of intravenous granisetron with metoclopramide plus dexamethasone in the prevention of nausea and vomiting associated with emetogenic cytotoxic chemotherapy. Kaohsiung J Med Sci. 1997 Feb;13(2):97-102. PubMed PMID: 9099048.

222: Tsukagoshi S. [A new antiemetic ramosetron hydrochloride]. Gan To Kagaku Ryoho. 1997 Feb;24(3):371-80. Review. Japanese. PubMed PMID: 9051143.

223: Ozono S, Okajima E, Hirao YK, Natsume O, Kaneko Y, Ohara S, Tabata S, Watanabe S, Aoyama H, Sasaki K, Matsuki H, Takashima K, Maruyama Y, Yoshikawa M, Yamada K, Momose H, Hiramatsu T, Hayashi Y, Babaya K, Shiomi T. [A comparative study of the effects of granisetron alone and a combination of granisetron plus steroids on CDDP-based combination chemotherapy-induced emesis--outcomes of a multicenter randomized comparative study using the central registration method. Nara Medical University Kytril Study Group]. Gan To Kagaku Ryoho. 1997 Feb;24(3):349-56. Japanese. PubMed PMID: 9051139.

224: Schwartz RH, Voth EA, Sheridan MJ. Marijuana to prevent nausea and vomiting in cancer patients: a survey of clinical oncologists. South Med J. 1997 Feb;90(2):167-72. PubMed PMID: 9042166.

225: Sekine I, Nishiwaki Y, Kakinuma R, Kubota K, Hojo F, Matsumoto T, Ohmatsu H, Yokozaki M, Goto K, Miyamoto T, Takafuji J, Kodama T. Phase II study of high-dose dexamethasone-based association in acute and delayed high-dose cisplatin-induced emesis--JCOG study 9413. Br J Cancer. 1997;76(1):90-2. PubMed PMID: 9218738; PubMed Central PMCID: PMC2223781.

226: Kigawa J, Minagawa Y, Itamochi H, Cheng X, Okada M, Terakawa N. Combination effect of granisetron and methylprednisolone for preventing emesis induced by cytotoxic agents. Gynecol Obstet Invest. 1997;43(3):195-9. PubMed PMID: 9127135.

227: Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health Syst Pharm. 1997 Jan 1;54(1):56-60. PubMed PMID: 9117791.

228: Kurita A, Takashima S, Nakata M, Kubo Y, Saiki T, Ohsumi S, Yokoyama N, Tanada M, Takiyama W, Saeki H. [Granisetron versus granisetron plus methylprednisolone in the prevention of chemotherapy induced nausea and vomiting--in adjuvant chemotherapy, including CDDP against gastric cancer]. Gan To Kagaku Ryoho. 1997 Jan;24(1):49-54. Japanese. PubMed PMID: 9020945.

229: Perez EA, Navari RM, Kaplan HG, Gralla RJ, Grunberg SM, Palmer RH, Fitts D. Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis. Support Care Cancer. 1997 Jan;5(1):31-7. PubMed PMID: 9010987.

230: Tremont-Lukats IW, Teixeira GM. Comparison of Granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer. A randomized controlled trial. Cancer. 1996 Dec 1;78(11):2450-3. PubMed PMID: 8941020.

231: Kris MG, Cubeddu LX, Gralla RJ, Cupissol D, Tyson LB, Venkatraman E, Homesley HD. Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin. Cancer. 1996 Nov 15;78(10):2193-8. PubMed PMID: 8918414.

232: Hargreaves AC, Gunthorpe MJ, Taylor CW, Lummis SC. Direct inhibition of 5-hydroxytryptamine3 receptors by antagonists of L-type Ca2+ channels. Mol Pharmacol. 1996 Nov;50(5):1284-94. PubMed PMID: 8913360.

233: Gerbino PP, Goldsmith M, Kenney JT Jr, Lindley C, Nolte J, Quan W, Reich PR. Antiemetic therapy in managed care oncology: roundtable discussion. Med Interface. 1996 Sep;Suppl C:16-35. PubMed PMID: 10161507.

234: Belkacémi Y, Ozsahin M, Pène F, Rio B, Sutton L, Laporte JP, Touboul E, Gorin NC, Laugier A. Total body irradiation prior to bone marrow transplantation: efficacy and safety of granisetron in the prophylaxis and control of radiation-induced emesis. Int J Radiat Oncol Biol Phys. 1996 Aug 1;36(1):77-82. PubMed PMID: 8823261.

235: Hisano C, Nakano S, Okuma K, Masumoto N, Fujishima H, Nakamura M, Niho Y. [Comparative trial of granisetron alone and granisetron plus methylprednisolone for prevention of nausea and vomiting during cancer chemotherapy]. Gan To Kagaku Ryoho. 1996 Aug;23(9):1175-81. Japanese. PubMed PMID: 8751806.

236: Silva RR, Bascioni R, Giorgi F, Acito L, Giustini L, De Signoribus G, Marcellini M, Menichetti ET, Giuliodori L. Granisetron plus dexamethasone in moderately emetogenic chemotherapy: evaluation of activity during three consecutive courses of chemotherapy. Support Care Cancer. 1996 Jul;4(4):287-90. PubMed PMID: 8829306.

237: Ettinger DS, Eisenberg PD, Fitts D, Friedman C, Wilson-Lynch K, Yocom K. A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy. Cancer. 1996 Jul 1;78(1):144-51. PubMed PMID: 8646710.

238: Massidda B, Ionta MT. Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy. J Chemother. 1996 Jun;8(3):237-42. PubMed PMID: 8808724.

239: Takigawa H, Naruo S, Kanayama H, Kagawa S, Yokoseki H, Inai T, Sumitani H, Sakurai N, Ogawa I, Akazawa S. [Efficacy of granisetron rescue therapy for nausea and vomiting induced by cancer chemotherapies in urogenital malignant tumor]. Gan To Kagaku Ryoho. 1996 Jun;23(7):899-903. Japanese. PubMed PMID: 8678539.

240: Sekine I, Nishiwaki Y, Kakinuma R, Kubota K, Hojo F, Matsumoto T, Ohmatsu H, Yokozaki M, Kodama T. A randomized cross-over trial of granisetron and dexamethasone versus granisetron alone: the role of dexamethasone on day 1 in the control of cisplatin-induced delayed emesis. Jpn J Clin Oncol. 1996 Jun;26(3):164-8. PubMed PMID: 8656557.

241: Plosker GL, Benfield P. Granisetron. A pharmacoeconomic evaluation of its use in the prophylaxis of chemotherapy-induced nausea and vomiting. Pharmacoeconomics. 1996 Apr;9(4):357-74. Review. PubMed PMID: 10160110.

242: Kataja V, de Bruijn KM. Hypersensitivity reactions associated with 5- hydroxytryptamine(3)-receptor antagonists: a class effect? Lancet. 1996 Mar 2;347(9001):584-5. PubMed PMID: 8596322.

243: Zhang P, Sun Y, Zhang H. [A randomized trial of tropisetron in the prophylaxis of nausea and vomiting induced by chemotherapy]. Zhonghua Zhong Liu Za Zhi. 1996 Mar;18(2):154-6. Chinese. PubMed PMID: 9206054.

244: Burris H, Hesketh P, Cohn J, Moriconi W, Ryan T, Friedman C, Fitts D. Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy. Cancer J Sci Am. 1996 Mar-Apr;2(2):85-90. PubMed PMID: 9166505.

245: Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Control of carboplatin-induced emesis with a fixed low dose of granisetron (0.5 mg) plus dexamethasone. Gynecol Oncol. 1996 Mar;60(3):435-7. PubMed PMID: 8774653.

246: Mantovani G, Macciò A, Bianchi A, Curreli L, Ghiani M, Proto E, Santona MC. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial. Cancer. 1996 Mar 1;77(5):941-8. PubMed PMID: 8608488.

247: Pinguet F, Bressolle F, Martel P, Salabert D, Astre C. High-performance liquid chromatographic determination of granisetron in human plasma. J Chromatogr B Biomed Appl. 1996 Jan 12;675(1):99-105. PubMed PMID: 8634776.

248: Slee PH, Rodenburg CJ. Venous thrombosis as a complication of antiemetic treatment. Cancer Chemother Pharmacol. 1996;38(6):574. PubMed PMID: 8823502.

249: Quigley C. 5HT3 receptor antagonists and pruritus due to cholestasis. Palliat Med. 1996 Jan;10(1):54. PubMed PMID: 8821191.

250: Gibbs SJ, Cassoni AM. A pilot study to evaluate the cost-effectiveness of ondansetron and granisetron in fractionated total body irradiation. Clin Oncol (R Coll Radiol). 1996;8(3):182-4. PubMed PMID: 8814373.

251: Martoni A, Angelelli B, Guaraldi M, Strocchi E, Pannuti F. An open randomised cross-over study on granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimens. Eur J Cancer. 1996 Jan;32A(1):82-5. PubMed PMID: 8695248.

252: Jantunen IT, Kataja VV, Muhonen TT, Parviainen T. Effects of granisetron with doxorubicin or epirubicin on ECG intervals. Cancer Chemother Pharmacol. 1996;37(5):502-4. PubMed PMID: 8599877.

253: Matsui K, Fukuoka M, Takada M, Kusunoki Y, Yana T, Tamura K, Yoshida T, Iida K, Hirashima T, Tsukada H, Ushijima S, Miyawaki H, Masuda N. Randomised trial for the prevention of delayed emesis in patients receiving high-dose cisplatin. Br J Cancer. 1996 Jan;73(2):217-21. PubMed PMID: 8546909; PubMed Central PMCID: PMC2074303.

254: Kitada M, Sawaragi I. [Clinical evaluation of granisetron hydrochloride against nausea and vomiting induced by anticancer drugs for gynecological malignant tumors]. Gan To Kagaku Ryoho. 1996 Jan;23(1):87-91. Japanese. PubMed PMID: 8546476.

255: Uchida K, Akaza H, Shimazui T, Kikuchi K, Manabe F, Iwasaki A, Ishikawa S, Noguchi R, Otani M, Hattori K, Kondo F, Nishijima Y, Sato K, Koiso K, Hinotsu S. [Comparison of clinical effects between granisetron alone and combination of granisetron and methylprednisolone against the nausea and vomiting induced by CDDP chemotherapy--comparative study by the cross-over trial. University of Tsukuba Antiemetics Study Group]. Gan To Kagaku Ryoho. 1996 Jan;23(1):81-6. Japanese. PubMed PMID: 8546475.

256: Adams VR, Valley AW. Granisetron: the second serotonin-receptor antagonist. Ann Pharmacother. 1995 Dec;29(12):1240-51. Review. PubMed PMID: 8672830.

257: Gebbia V, Testa A, Valenza R, Cannata G, Tirrito ML, Gebbia N. Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. A prospective randomized trial. Cancer. 1995 Nov 15;76(10):1821-8. PubMed PMID: 8625054.

258: Tsukuda M, Mochimatsu I, Furukawa M, Kohno H, Kawai S, Enomoto H, Yago T, Matsuda H, Ikema Y, Zhou L. [A randomized crossover comparison of azasetron and granisetron in the prophylaxis of emesis induced by chemotherapy including cisplatin]. Gan To Kagaku Ryoho. 1995 Nov;22(13):1959-67. Japanese. PubMed PMID: 7487127.

259: Ito C, Isobe Y, Kijima H, Kiuchi Y, Ohtsuki H, Kawamura R, Tsuchida K, Higuchi S. The anti-emetic activity of GK-128 in Suncus murinus. Eur J Pharmacol. 1995 Oct 4;285(1):37-43. PubMed PMID: 8846809.

260: Contu A, Olmeo N, Piro S, Sabbatini R, Depenni R, Silingardi V, Zaniboni A, Meriggi F, Donati D, Maestri A, et al. A comparison of the antiemetic efficacy and safety of intramuscular and intravenous formulations of granisetron in patients receiving moderately emetogenic chemotherapy. Anticancer Drugs. 1995 Oct;6(5):652-6. PubMed PMID: 8845475.

261: Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Italian Group of Antiemetic Research. Ann Oncol. 1995 Oct;6(8):805-10. PubMed PMID: 8589019.

262: Nukariya N, Nakarai I, Kobayashi H, Koizumi W, Komatsu H, Uchiyama T, Yamaguchi T, Taira O, Minato K, Futatsugi K, et al. [A comparative study of the effect of granisetron and a combination of granisetron plus steroids on cancer chemotherapy induced emesis]. Gan To Kagaku Ryoho. 1995 Oct;22(12):1821-9. Japanese. PubMed PMID: 7574816.

263: Cleri LB, Kris MG, Tyson LB, Pisters KM, Clark RA, Gralla RJ. Oral combination antiemetics in patients with small cell lung cancer receiving cisplatin or cyclophosphamide plus doxorubicin. Cancer. 1995 Sep 1;76(5):774-8. PubMed PMID: 8625179.

264: Maisano R, Adamo V, Settineri N, Pergolizzi S, Scimone A, Altavilla G. Efficacy of two oral dose regimens of granisetron. Anticancer Res. 1995 Sep-Oct;15(5B):2287-90. PubMed PMID: 8572639.

265: Pronzato P, Losardo PL, Vaira F, Vigani A, Landucci M, Ghio E. Granisetron-dexamethasone combination for multiple day cisplatin. Anticancer Res. 1995 Sep-Oct;15(5B):2261-3. PubMed PMID: 8572634.

266: Latreille J, Stewart D, Laberge F, Hoskins P, Rusthoven J, McMurtrie E, Warr D, Yelle L, Walde D, Shepherd F, et al. Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy. Support Care Cancer. 1995 Sep;3(5):307-12. PubMed PMID: 8520877.

267: Yamasaki T, Konishi S, Kagawa T, Nagai H, Nagao S, Moritake K. [The efficacy of granisetron as a prophylactic anti-emetic agent used in conjunction with MCNU and VP16 chemotherapeutic regimens in the management of a pediatric case of hypothalamic anaplastic astrocytoma]. Gan To Kagaku Ryoho. 1995 Sep;22(10):1397-402. Japanese. PubMed PMID: 7668877.

268: Tsukuda M, Kohno H, Enomoto H, Kawai S, Yago T, Matsuda H, Ikema Y, Makino Y, Kubota A, Furukawa M. [Comparison of granisetron alone and granisetron plus dexamethasone or hydroxyzine hydrochloride for the prevention of nausea and vomiting during chemotherapy including cisplatin]. Gan To Kagaku Ryoho. 1995 Sep;22(10):1377-82. Japanese. PubMed PMID: 7668873.

269: Persistence of efficacy of three antiemetic regimens and prognostic factors in patients undergoing moderately emetogenic chemotherapy. Italian Group for Antiemetic Research. J Clin Oncol. 1995 Sep;13(9):2417-26. PubMed PMID: 7666102.

270: Tsukuda M, Furukawa S, Kokatsu T, Enomoto H, Kubota A, Furukawa M. Comparison of granisetron alone and granisetron plus hydroxyzine hydrochloride for prophylactic treatment of emesis induced by cisplatin chemotherapy. Eur J Cancer. 1995 Sep;31A(10):1647-9. PubMed PMID: 7488417.

271: Fedele P, Spina M, Valentini M, Collini D, Lucia C, Manicone M, Tirelli U. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Cancer. 1995 Aug 1;76(3):535-6. PubMed PMID: 8625142.

272: Morrow GR, Hickok JT, Rosenthal SN. Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban). Cancer. 1995 Aug 1;76(3):343-57. Review. PubMed PMID: 8625113.

273: Craft AW, Price L, Eden OB, Shaw P, Campbell R, Pierce DM, Murdoch R, Upward J. Granisetron as antiemetic therapy in children with cancer. Med Pediatr Oncol. 1995 Jul;25(1):28-32. PubMed PMID: 7752999.

274: Navari R, Gandara D, Hesketh P, Hall S, Mailliard J, Ritter H, Friedman C, Fitts D. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group. J Clin Oncol. 1995 May;13(5):1242-8. PubMed PMID: 7738628.

275: Stewart A, McQuade B, Cronje JD, Goedhals L, Gudgeon A, Corette L, Froger X, Tubiana-Hulin M, Laplaige P, Roberts JT, et al. Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: a multicentre, double-blind, double-dummy, randomised, parallel-group study. Emesis Study Group for Ondansetron and Granisetron in Breast Cancer Patients. Oncology. 1995 May-Jun;52(3):202-10. PubMed PMID: 7715904.

276: Hayashida S, Hirasawa T, Uchiyama K, Mitsui H, Nasu T, Shinohara Y. [The preventive effect of granisetron on digestive tract symptoms induced by arterial infusion of anticancer and hypertensive agents in combination with radiotherapy--a study of forty patients with bladder cancer]. Gan To Kagaku Ryoho. 1995 Apr;22(5):639-46. Japanese. PubMed PMID: 7717715.

277: Eguchi F, Shindo M, Emoto M, Mohtai H, Hachisuga T, Kawarabayashi T, Shirakawa K. [The prevention of cancer chemotherapy-induced emesis with granisetron and clonazepam]. Gan To Kagaku Ryoho. 1995 Feb;22(2):233-7. Japanese. PubMed PMID: 7857098.

278: Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. The Italian Group for Antiemetic Research. N Engl J Med. 1995 Jan 5;332(1):1-5. PubMed PMID: 7990859.

279: Gale JD. Serotonergic mediation of vomiting. J Pediatr Gastroenterol Nutr. 1995;21 Suppl 1:S22-8. Review. PubMed PMID: 8708863.

280: Adam Z, Coupková H, Kolek V, Kucera M, Loffelmann L, Martinez A, Nováková M, Průsa P, Reiterer P, Skalová B, et al. Vinorelbine and cisplatin in the treatment of advanced non-small cell lung cancer: results of a multicenter Czech study. Acta Med Austriaca. 1995;22(5):120-4. PubMed PMID: 8651041.

281: Watanabe H, Hasegawa A, Shinozaki T, Arita S, Chigira M. Possible cardiac side effects of granisetron, an antiemetic agent, in patients with bone and soft-tissue sarcomas receiving cytotoxic chemotherapy. Cancer Chemother Pharmacol. 1995;35(4):278-82. PubMed PMID: 7828269.

282: Bleiberg HH, Spielmann M, Falkson G, Romain D. Antiemetic treatment with oral granisetron in patients receiving moderately emetogenic chemotherapy: a dose-ranging study. Clin Ther. 1995 Jan-Feb;17(1):38-51. PubMed PMID: 7758060.

283: Behnam Motlagh P, Henriksson R, Grankvist K. Interaction of the antiemetics ondansetron and granisetron with the cytotoxicity induced by irradiation, epirubicin, bleomycin, estramustine, and cisplatin in vitro. Acta Oncol. 1995;34(6):871-5. PubMed PMID: 7576757.

284: Debrix I, Puteaux S, Milleron B, Becker A. [Efficacy of the granisetron/solumedrol combination in the control of drug-induced acute nausea and vomiting. Results of a prospective survey]. Ann Pharm Fr. 1995;53(4):170-5. French. PubMed PMID: 7574271.

285: Herrstedt J. Development of antiemetic therapy in cancer patients. Acta Oncol. 1995;34(5):637-40. Review. PubMed PMID: 7546831.

286: Golaszewski T, Kölbl H, Lahousen M, Staab HJ. [Granisetron, a antiemetic for treatment of cytostatic drug-induced vomiting: results of a practice-oriented study]. Wien Klin Wochenschr. 1995;107(20):613-21. German. PubMed PMID: 7502509.

287: Carmichael J, Philip PA, Forfar C, Harris AL. An open study to assess the safety, tolerance and pharmacokinetics of an intravenous infusion of granisetron given at 3 mg over 30 s in patients receiving chemotherapy for malignant disease. Cancer Chemother Pharmacol. 1995;37(1-2):134-8. PubMed PMID: 7497582.

288: Tanioka Y, Fujii T, Nakata N, Nakagawa H, Tanimoto H, Kioka H, Naito H. [Antiemetic efficacy of the repeated use of granisetron in multiple cycles of anti-cancer chemotherapy]. Gan To Kagaku Ryoho. 1994 Dec;21(16):2803-8. Japanese. PubMed PMID: 7993117.

289: Adam Z, Mayer J, Hájek R. [Cisplatin and carboplatin in the treatment of malignant lymphoma and multiple myeloma]. Vnitr Lek. 1994 Dec;40(12):790-800. Review. Czech. PubMed PMID: 7839634.

290: Kaufman MB. Adverse effects associated with dexamethasone, lorazepam, and granisetron. Ann Pharmacother. 1994 Nov;28(11):1306-7. PubMed PMID: 7849354.

291: Ohmatsu H, Eguchi K, Shinkai T, Tamura T, Ohe Y, Nisio M, Kunikane H, Arioka H, Karato A, Nakashima H, et al. A randomized cross-over study of high-dose metoclopramide plus dexamethasone versus granisetron plus dexamethasone in patients receiving chemotherapy with high-dose cisplatin. Jpn J Cancer Res. 1994 Nov;85(11):1151-8. PubMed PMID: 7829401.

292: Bresciani G, Böhm S, Oriana S. Control of nausea and vomiting by granisetron in ovarian cancer patients treated with different cisplatin-based regimens. Tumori. 1994 Oct 31;80(5):344-7. PubMed PMID: 7839463.

293: Kudoh S, Sato T, Okada H, Kumakura H, Nakamura H. Simultaneous determination of granisetron and 7-hydroxygranisetron in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Appl. 1994 Oct 3;660(1):205-10. PubMed PMID: 7858717.

294: Gebbia V, Cannata G, Testa A, Curto G, Valenza R, Cipolla C, Latteri MA, Gebbia N. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial. Cancer. 1994 Oct 1;74(7):1945-52. PubMed PMID: 8082100.

295: Navari RM, Kaplan HG, Gralla RJ, Grunberg SM, Palmer R, Fitts D. Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol. 1994 Oct;12(10):2204-10. PubMed PMID: 7931490.

296: Kris MG, Pisters KM, Hinkley L. Delayed emesis following anticancer chemotherapy. Support Care Cancer. 1994 Sep;2(5):297-300. Review. PubMed PMID: 8000726.

297: Tonato M, Roila F, Del Favero A. Are there differences among the serotonin antagonists? Support Care Cancer. 1994 Sep;2(5):293-6. Review. PubMed PMID: 8000725.

298: Numa Y, Kasai H, Imahori T, Tsuchida T, Kawamoto K. [Effective measures against side effects by increasing ACNU dose for malignant glioma: effects on digestive organs]. Gan To Kagaku Ryoho. 1994 Sep;21(12):2029-33. Japanese. PubMed PMID: 7522001.

299: Hamada T, Kuwahara T, Ida M, Hayasaka S, Yoshinaga T, Kawano S, Ushijima M, Matsumura K, Ueda K, Nomura H, et al. [Clinical effects and safety of granisetron administration against CDDP chemotherapy in lung cancer. Lung Cancer Study Group]. Gan To Kagaku Ryoho. 1994 Aug;21(10):1647-53. Japanese. PubMed PMID: 8060141.

300: Yoshiya N, Kodama S, Tanaka K, Hataya I, Tokunaga A, Takeuchi Y, Hanaoka J, Yanase T, Takahashi T, Maruhashi T, et al. [Clinical evaluation of granisetron injection against nausea and vomiting induced by anticancer drugs including cisplatin]. Gan To Kagaku Ryoho. 1994 Aug;21(10):1641-6. Japanese. PubMed PMID: 8060140.

301: Miyajima Y, Numata S, Katayama I, Horibe K. Prevention of chemotherapy-induced emesis with granisetron in children with malignant diseases. Am J Pediatr Hematol Oncol. 1994 Aug;16(3):236-41. PubMed PMID: 8037342.

302: Jacobson SJ, Shore RW, Greenberg M, Spielberg SP. The efficacy and safety of granisetron in pediatric cancer patients who had failed standard antiemetic therapy during anticancer chemotherapy. Am J Pediatr Hematol Oncol. 1994 Aug;16(3):231-5. PubMed PMID: 8037341.

303: Noguchi S, Kubota Y, Shuin T, Masuda M, Misaki H, Yao M, Kondoh K, Sakuramoto T, Hosaka M. [M-VAC chemotherapy for advanced urothelial cancer--side effects and their management]. Hinyokika Kiyo. 1994 Aug;40(8):677-82. Japanese. PubMed PMID: 7942364.

304: Granisetron to prevent vomiting after cancer chemotherapy. Med Lett Drugs Ther. 1994 Jul 8;36(926):61-2. PubMed PMID: 8015512.

305: Eisenberg PD. Further profiles of granisetron (Kytril): effect on quality of life and pharmacoeconomics. Semin Oncol. 1994 Jun;21(3 Suppl 5):26-9. Review. PubMed PMID: 8042034.

306: Palmer R. Efficacy and safety of granisetron (Kytril) in two special patient populations: children and adults with impaired hepatic function. Semin Oncol. 1994 Jun;21(3 Suppl 5):22-5. Review. PubMed PMID: 8042033.

307: Perez EA, Gandara DR. The clinical role of granisetron (Kytril) in the prevention of chemotherapy-induced emesis. Semin Oncol. 1994 Jun;21(3 Suppl 5):15-21. Review. PubMed PMID: 8042032.

308: Dilly S. Granisetron (Kytril) clinical safety and tolerance. Semin Oncol. 1994 Jun;21(3 Suppl 5):10-4. Review. PubMed PMID: 8042031.

309: Ignoffo RJ. Granisetron. Cancer Pract. 1994 May-Jun;2(3):229-31. PubMed PMID: 8055027.

310: Tan EH, Ang PT, Khoo KS. Control of emesis by intravenous granisetron in breast cancer patients treated with 5-FU, epirubicin and cyclophosphamide. Support Care Cancer. 1994 May;2(3):197-200. PubMed PMID: 8032707.

311: Soukop M. A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer. 1994 May;2(3):177-83. PubMed PMID: 8032704.

312: Pater J, Slamet L, Zee B, Osoba D, Warr D, Rusthoven J. Inconsistency of prognostic factors for post-chemotherapy nausea and vomiting. Support Care Cancer. 1994 May;2(3):161-6. PubMed PMID: 8032701.

313: Hirota T, Shimizu H, Fujimoto T, Koike A, Kojima T, Noguchi M, Yabushita H, Kato R, Daimaru O, Noda A, et al. [Comparative trial of granisetron versus granisetron plus methylprednisolone for the prevention of nausea and vomiting induced by cancer chemotherapy]. Gan To Kagaku Ryoho. 1994 Jan;21(1):91-6. Japanese. PubMed PMID: 8291920.

314: Ruff P, Paska W, Goedhals L, Pouillart P, Rivière A, Vorobiof D, Bloch B, Jones A, Martin C, Brunet R, et al. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. The Ondansetron and Granisetron Emesis Study Group. Oncology. 1994 Jan-Feb;51(1):113-8. Erratum in: Oncology 1994 May-Jun;51(3):243. PubMed PMID: 8265095.

315: Regidor PA, Schindler AE. [Granisetron, a new and potent antiemetic for treatment of cytostatic drug-induced vomiting in gynecological malignancies]. Geburtshilfe Frauenheilkd. 1994 Jan;54(1):51-4. German. PubMed PMID: 8150251.

316: Noble A, Bremer K, Goedhals L, Cupissol D, Dilly SG. A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. The Granisetron Study Group. Eur J Cancer. 1994;30A(8):1083-8. PubMed PMID: 7654434.

317: Cupissol D, Bressolle F, Adenis L, Carmichael J, Bessell E, Allen A, Wargenau M, Romain D. Evaluation of the bioequivalence of tablet and capsule formulations of granisetron in patients undergoing cytotoxic chemotherapy for malignant disease. J Pharm Sci. 1993 Dec;82(12):1281-4. PubMed PMID: 8308713.

318: Hirota T, Honjo T, Kuroda R, Saeki K, Katano N, Sakakibara Y, Shimizu H, Fujimoto T. [Antiemetic efficacy of granisetron in pediatric cancer treatment--(2). Comparison of granisetron and granisetron plus methylprednisolone as antiemetic prophylaxis]. Gan To Kagaku Ryoho. 1993 Dec;20(15):2369-73. Japanese. PubMed PMID: 8259853.

319: Tsukagoshi S, Ohta J, Taguchi T. [An outline of 5-HT3 receptor antagonists (2)--In clinical applications]. Gan To Kagaku Ryoho. 1993 Dec;20(15):2276-81. Review. Japanese. PubMed PMID: 8259839.

320: Kris MG, Baltzer L, Pisters KM, Tyson LB. Enhancing the effectiveness of the specific serotonin antagonists. Combination antiemetic therapy with dexamethasone. Cancer. 1993 Dec 1;72(11 Suppl):3436-42. Review. PubMed PMID: 8242576.